Skip to content

COMMENTS & FEEDBACK
Check HbA1c
Check HbA1c
< 42 mmol/mol
< 42 mmol/mol
42 - 47 mmol/mol
42 - 47 mmol/mol
≥ 48 mmol/mol
≥ 48 mmol/mol
Normal
Follow up as appropriate
Normal...
Non-Diabetic
 Hyperglycaemia
Non-Diabetic...
• Code as Non-Diabetic Hyperglycaemia
(C317. in EMIS or XaaeP in SystmOne)
• Lifestyle advice
• Refer to NDPP / Structured education / Intensive                        lifestyle management where available
• 6-12 monthly follow-up
• Code as Non-Diabetic Hyperglycaemia...
NO
NO
YES
YES
Symptoms?
Symptoms?
Repeat HbA1c within 2 weeks 
Repeat HbA1c within 2 weeks 
42 - 47 mmol/mol
42 - 47 mmol/mol
≥ 48 mmol/mol
≥ 48 mmol/mol

• Code Diabetes type if possible
• Refer if suspected Type 1 or Pregnant or MODY
• Refer structured education
• Refer retinal screening
• Arrange regular follow up
• Refer to Remission programme if eligible
• Carry out mental health screening (PHQ4 in primary and community care OR DDS2 in secondary care) and consider referral to IAPT or other relevant part of local pathway if positive

• Code Diabetes type if possible...
Normal
Normal
High risk of Diabetes
High risk of Diabetes
Diabetes
Diabetes
HbA1c
HbA1c
< 42 mmol/mol
< 42 mmol/mol
42 - 47 mmol/mol
42 - 47 mmol/mol
≥ 48 mmol/mol
≥ 48 mmol/mol
Fasting Glucose
Fasting Glucose
≤ 5.4 mmol/L
≤ 5.4 mmol/L
5.5 - 6.9 mmol/L
5.5 - 6.9 mmol/L
≥ 7.0 mmol/L
≥ 7.0 mmol/L
2 hour Glucose in OGT 
2 hour Glucose in OGT 
≤ 7.7 mmol/L
≤ 7.7 mmol/L
7.8 - 11.0 mmol/L
7.8 - 11.0 mmol/L
≥ 11.1 mmol/L
≥ 11.1 mmol/L
Random Glucose
Random Glucose
≥ 11.1 mmol/L
≥ 11.1 mmol/L
Source: North West London Type 2 Diabetes Guidelines
Source: North West London Type 2 Diabetes Guidelines
WHEN NOT TO USE HBA1C TO DIAGNOSE DIABETES 
WHEN NOT TO USE HBA1C TO DIAGNOSE DIABETES 
Text is not SVG - cannot display
View Classification Pathway
Cardiff Guidelines
Cardiff Guidelines
T1 Diabetes Features
T1 Diabetes Features

● Progression to insulin within 3 years
● BMI (< 25 for sens/spec*)
● Age at diagnosis (< 30 for sens/spec* other guidelines < 35)
● Weight loss
● Diagnosis HbA1c (>115 mmol/mol) or Glucose (>20mmol/L)
● Lack of FH diabetes
● Osmotic symptoms 
● DKA
● Other autoimmune disease

● Progression to insulin within 3 years...
T1/T2 Prediction Model
T1/T2 Prediction Model
T2 Diabetes Features
T2 Diabetes Features

● BMI at diagnosis > 25
● Absence of weight loss
● Absence of Ketoacidosis
● Less marked hyperglycaemia
● Weak discriminators - Non-white ethnicity  

● BMI at diagnosis > 25...
- Family history of Diabetes 
- Longer duration/mild severity of    symptoms prior to presentation 
- Features of metobolic syndrome 
- No Fhx of autoimmunity
- Family history of Diabetes...
MODY Features
MODY Features

● Age < 35 
● HbA1c < 58 mmol/mol at diagnosis
● Parent with Diabetes
● Features of a specific monogenic cause (e.g., 
      renal cysts, 
      partial lipodystrophy, 
      maternally inherited deafness, and 
      severe insulin resistance in the absence of obesity)
● Monogenic diabetes prediction model probability >5%

● Age < 35...
ABCD
ABCD
ADA 2024
ADA 2024
ADA 2024
ADA 2024
*Exeter 
*Exeter 
AABBCC approach
AABBCC approach
Exeter MODY calculator
Exeter MODY calculator
NHS testing criteria
NHS testing criteria
ADA Flowchart
ADA Flowchart
ADA 2024
ADA 2024
Age
Age
A
A
Autoimmunity
Autoimmunity
A
A
Body habitus
Body habitus
B
B
Background
Background
B
B
Control
Control
C
C
Comorbidities
Comorbidities
C
C
(e.g., personal or family history of autoimmune disease or polyglandular autoimmune syndromes)
(e.g., personal or family history of autoimmune disease or p...
(e.g., for individuals <35 years old, consider type 1 diabetes)
(e.g., for individuals <35 years old, consider type 1 diabet...
(e.g., BMI <25 kg/m2)
(e.g., BMI <25 kg/m2)
(e.g., family history of type 1 diabetes)
(e.g., family history of type 1 diabetes)
(e.g., level of glucose control on noninsulin therapies)
(e.g., level of glucose control on noninsulin therapies)
(e.g., treatment with immune checkpoint inhibitors for cancer can cause acute autoimmune type 1 diabetes)
(e.g., treatment with immune checkpoint inhibitors for cance...
C-Peptide testing
C-Peptide testing
PCDS: How to diagnose and manage steroid-induced diabetes and hyperglycaemia
PCDS: How to diagnose and manage steroid-induced diabetes and hyperglycaemia
PCDS: Recognition and management of pancreatogenic (type 3c) diabetes
PCDS: Recognition and management of pancreatogenic (type 3c) diabetes
Text is not SVG - cannot display
View MODY Pathway
T1 Diabetes Features
T1 Diabetes Features
T1/T2 Prediction Model
T1/T2 Prediction Model
T2 Diabetes Features
T2 Diabetes Features
MODY Features
MODY Features
ABCD
ABCD
ADA 2024
ADA 2024
ADA 2024
ADA 2024
*Exeter 
*Exeter 
AABBCC approach
AABBCC approach
Exeter MODY calculator
Exeter MODY calculator
NHS testing criteria
NHS testing criteria
ADA Flowchart
ADA Flowchart
ADA 2024
ADA 2024
or
Diabetes diagnosed young
Diabetes diagnosed young
1
1
Unlikely to have Type 1 Diabetes
Unlikely to have Type 1 Diabetes
2
2
Have features suggestive of MODY
Have features suggestive of MODY
3
3
≤ 35 years in White Europeans
≤ 35 years in White Europeans
or
≤ 30 years in high prevalence ethnic groups
≤ 30 years in high prevalence ethnic groups
Not on insulin treatment
Not on insulin treatment
or
all autoantibodies* tested negative 
and 
a random non-fasting
C peptide value ≥ 200pmol/L
all autoantibodies* tested negative...
An HbA1c at diagnosis < 58mmol/mol
An HbA1c at diagnosis < 58mmol/mol
BMI < 27 and a parent with diabetes
BMI < 27 and a parent with diabetes
Have a MODY probability score ≥ 20%
Have a MODY probability score ≥ 20%
if diagnosed 
under 18 years of age
if diagnosed...
BMI < 30 and a parent with diabetes (if White)
BMI < 30 and a parent with diabetes (if Whi...
 if high prevalence type 2 diabetes ethnic group
if high prevalence type 2 diabetes ethnic...
if not insulin treated, and ≥10% if insulin treated.
if not insulin treated, and ≥10% if insulin...
On insulin treatment with
On insulin treatment with
like South Asians
like South Asians
*minimum testing of GADA and IA2A
*minimum testing of GADA and IA2A
Glucokinase-related fasting hyperglycaemia (R142)
Glucokinase-related fasting hyperglycaemia (R142)
Neonatal diabetes (R143)
Neonatal diabetes (R143)
Syndromic diabetes (R141)
Syndromic diabetes (R141)
Diabetes with severe insulin resistance (R141)
Diabetes with severe insulin resistance (R141)
Referral Forms
Referral Forms

● Progression to insulin within 3 years
● BMI (< 25 for sens/spec*)
● Age at diagnosis (< 30 for sens/spec* other guidelines < 35)
● Weight loss
● Diagnosis HbA1c (>115 mmol/mol) or Glucose (>20mmol/L)
● Lack of FH diabetes
● Osmotic symptoms 
● DKA
● Other autoimmune disease

● Progression to insulin within 3 years...

● BMI at diagnosis > 25
● Absence of weight loss
● Absence of Ketoacidosis
● Less marked hyperglycaemia
● Weak discriminators - Non-white ethnicity  

● BMI at diagnosis > 25...
- Family history of Diabetes 
- Longer duration/mild severity of    symptoms prior to presentation 
- Features of metobolic syndrome 
- No Fhx of autoimmunity
- Family history of Diabetes...

● Age < 35 
● HbA1c < 58 mmol/mol at diagnosis
● Parent with Diabetes
● Features of a specific monogenic cause (e.g., 
      renal cysts, 
      partial lipodystrophy, 
      maternally inherited deafness, and 
      severe insulin resistance in the absence of obesity)
● Monogenic diabetes prediction model probability >5%

● Age < 35...
Cardiff Guidelines
Cardiff Guidelines
C-Peptide testing
C-Peptide testing
NHS Guidelines For Genetic Testing In MODY
NHS Guidelines For Genetic Testing In MODY
PCDS: How to diagnose and manage steroid-induced diabetes and hyperglycaemia
PCDS: How to diagnose and manage steroid-induced diabetes and hyperglycaemia
PCDS: Recognition and management of pancreatogenic (type 3c) diabetes
PCDS: Recognition and management of pancreatogenic (type 3c) diabetes
Text is not SVG - cannot display
View AABBCC Diagram
View all links
YES
YES
Symptoms of hyperglycaemia and a diagnostic
blood glucose (random > 11.1mmol/L)
Symptoms of hyperglycaemia and a diagnostic...
NO
NO
YES
YES
 Is the patient ill 
(vomiting, semiconscious or clinically dehydrated)?
Is the patient ill...
NO
NO
YES
YES
Does the urine test show moderate/heavy
ketonuria?
Does the urine test show moderate/heavy...
NO
NO
%3CmxGraphModel%3E%3Croot%3E%3CmxCell%20id%3D%220%22%2F%3E%3CmxCell%20id%3D%221%22%20parent%3D%220%22%2F%3E%3CmxCell%20id%3D%222%22%20value%3D%22%26lt%3Bspan%20style%3D%26quot%3Bfont-size%3A%2014px%3B%26quot%3B%26gt%3BYES%26lt%3B%2Fspan%26gt%3B%22%20style%3D%22edgeLabel%3Bhtml%3D1%3Balign%3Dcenter%3BverticalAlign%3Dmiddle%3Bresizable%3D0%3Bpoints%3D%5B%5D%3B%22%20vertex%3D%221%22%20connectable%3D%220%22%20parent%3D%221%22%3E%3CmxGeometry%20x%3D%22390%22%20y%3D%22421%22%20as%3D%22geometry%22%2F%3E%3C%2FmxCell%3E%3C%2Froot%3E%3C%2FmxGraphModel%3E
%3CmxGraphModel%3E%3Croot%3E%3CmxCell%20id%3D%220%22%2F%3E%3CmxCell%20id%3D%221%22%20parent%3D%220%22%2F%3E%3CmxCell%20id%3D%222%22%20value%3D%22%26lt%3Bspan%20style%3D%26quot%3Bfont-size%3A%2014px%3B%26quot%3B%26gt%3BYES%26lt%3B%2Fspan%26gt%3B%22%20style%3D%22edgeLabel%3Bhtml%3D1%3Balign%3Dcenter%3BverticalAlign%3Dmiddle%3Bresizable%3D0%3Bpoints%3D%5B%5D%3B%22%20vertex%3D%221%22%20connectable%3D%220%22%20parent%3D%221%22%3E%3CmxGeometry%20x%3D%22390%22%20y%3D%22421%22%20as%3D%22geometry%22%2F%3E%3C%2FmxCell%3E%3C%2Froot%3E%3C%2FmxGraphModel%3E
YES
YES

Are one or more of the following present?
  • ● Severe osmotic symptoms (nocturia x 3-4)
  • ● Short history (weeks)
  • ● Marked weight loss (irrespective of absolute weight)
  • ● A first degree relative with Type 1 Diabetes
  • ● A personal history of autoimmune disease
Are one or more of the following present?...
NO
NO
YES
YES
 Is the patient under 30 years of age?
 Is the patient under 30 years of age?
There is no immediate need for insulin. 
Give dietary advice on healthy eating. 
 Provide regular review.
There is no immediate need for insulin....
Arrange direct admission to hospital
Arrange direct admission to hospital
 Very likely to need insulin. Discuss with specialist team within 24 hours.
Very likely to need insulin. Discuss with speci...
Two or more are a strong indication for insulin
Two or more are a strong indication for insulin
First degree relative on diet or tablets consider maturity Onset Diabetes of the Young (MODY).

No immediate need for insulin but non urgent referral to the specialist team for diagnostic consideration.
First degree relative on diet or tablets conside...
Adapted from NWL Type 2 Diabetes Guidelines
Adapted from NWL Type 2 Diabetes Guidelines
DIABETES – NEW DIAGNOSIS: TREATMENT DECISION TREE FOR EARLY INSULIN INITIATION
DIABETES – NEW DIAGNOSIS: TREATMENT DECISION TREE FOR EARLY INSULIN INITIATION
RACGP: Emergency management of hyperglycaemia in primary care
RACGP: Emergency management of hyperglycaemia in...
Clinical assessment
Clinical assessment
Person not known to have diabetes
Person not known to have diabetes
Person known to have diabetes
Person known to have diabetes
BLOOD KETONES NOW RECOMMENDED
BLOOD KETONES NOW RECOMMENDED
PCDS: Ketones and diabetes
PCDS: Ketones and diabetes
JBSD-IP: Management of Hyperglycaemia and
Steroid (Glucocorticoid) Therapy
JBSD-IP: Management of Hyperglycaemia and...
Assessment of hyperglycaemia
Assessment of hyperglycaemia
Management of hyperglycaemia
Management of hyperglycaemia
PCDS: How to diagnose and manage steroid-induced diabetes and hyperglycaemia
PCDS: How to diagnose and manage steroid-induc...
CKS
CKS
T1 Diabetes
T1 Diabetes
CKS
CKS
suspected DKA
suspected DKA
CKS
CKS
suspected T2D
suspected T2D
CKS
CKS
T2D Management
T2D Management
PCDS: A guide to sulfonylureas
PCDS: A guide to sulfonylureas
NICE
NICE
Rescue Treatment
Rescue Treatment
CKS
CKS
Sulfonylureas
Sulfonylureas
CKS
CKS
Insulin Therapy
Insulin Therapy
Text is not SVG - cannot display
Initial Management
Initial Management
!
!
Confirm the Diagnosis
Confirm the Diagnosis
Consider the Classification
Consider the Classification
Manage symptomatic Hyperglycaemia
Manage symptomatic Hyperglycaemia
Adopt an individualised approach to diabetes care and offer structured education
Adopt an individualised approach to diabetes care and offer structured education
Individualise Glycaemic Targets
Individualise Glycaemic Targets
Advise Lifestyle changes for the prevention of CVD
Advise Lifestyle changes for the prevention of CVD
Advise Lifestyle changes
Advise Lifestyle changes
Offer Structured Education
Offer Structured Education
NICE
NICE
HbA1c Targets
HbA1c Targets
NICE
NICE
Education
Education
Dietary advice
Dietary advice
NICE
NICE
Text is not SVG - cannot display
Confirm the Diagnosis
Consider the Classification
Manage Symptomatic Hyperglycaemia
Hidden
Initial Management Full
NWL GUIDELINES
If intolerant move down to next level
If intolerant move down to next l...
AND
AND
Metformin+ SGLT2i
STOP DPP4i
STOP DPP4i
NWL
NWL
New Diagnosis and Early insulin initiation
New Diagnosis and Early insulin initiat...
NWL
NWL
Screening and Diagnosis
Screening and Diagnosis
T1D vs T2D
T1D vs T2D
MODY
MODY
NWL
NWL
Algorithm
Algorithm
NWL
NWL
NWL
NWL
HbA1c targets
HbA1c targets
NWL
NWL
Hypoglycaemic agents with insulin
Hypoglycaemic agents with insulin
NWL
NWL
Sequential insulin strategies
Sequential insulin strategies
+ DPP4i+ GLP-1 RA+ Sulfonylurea+ Basal Insulin
Preferred: Empagliflozin
Preferred: Empagliflozin
Preferred: Sitagliptin
Preferred: Sitagliptin
Preferred: S/C Semaglutide
Preferred: S/C Semaglutide
Alternative: Canagliflozin
Alternative: Canagliflo...
Alternative: Dulaglutide
Alternative: Dulaglutide
NWL
NWL
Metformin
Metformin
NWL
NWL
SGLT2 inhibitors
SGLT2 inhibitors
NWL
NWL
DPP4 inhibitors
DPP4 inhibitors
NWL
NWL
GLP-1 Receptor Agonists
GLP-1 Receptor Agonists
NWL
NWL
Basal insulin
Basal insulin
Starting and reviewing
Starting and reviewing
NWL
NWL
Sulfonylurea
Sulfonylurea
NWL
NWL
Summary of anti-diabetic agents
Summary of anti-diabetic agents
NWL
NWL
Dose adjustment in renal/hepatic impairment
Dose adjustment in renal/hepatic impairment
Insulin pen devices
Insulin pen devices
NWL
NWL
Insulin regimens
Insulin regimens
NWL
NWL
BD mixed insulin
BD mixed insulin
Starting and reviewing
Starting and reviewing
NWL
NWL
Indications for insulin
Indications for insul...
Insulin initiation
Insulin initiat...
Choice of insulin
Choice of insulin
NWL
NWL
Structured Education
Structured Education
Diet & Lifestyle first line therapy
Diet & Lifestyle first line the...
Remission
Remission
Weight loss and lifestyle change
Weight loss and lifestyle change
Sick day guidance
Sick day guidance
Text is not SVG - cannot display
+
+
+
+
+
+
Manage Symptomatic Hyperglycaemia
GLP-1 RA shortage guidance
If intolerant move down to next level
If intolerant move down to next l...
AND
AND
Metformin+ SGLT2i
STOP DPP4i
STOP DPP4i
NWL
NWL
New Diagnosis and Early insulin initiation
New Diagnosis and Early insulin initiat...
NWL
NWL
Screening and Diagnosis
Screening and Diagnosis
T1D vs T2D
T1D vs T2D
MODY
MODY
NWL
NWL
Algorithm
Algorithm
NWL
NWL
NWL
NWL
HbA1c targets
HbA1c targets
NWL
NWL
Hypoglycaemic agents with insulin
Hypoglycaemic agents with insulin
NWL
NWL
Sequential insulin strategies
Sequential insulin strategies
+ GLP-1 RA+ Sulfonylurea+ Basal Insulin
Preferred: Dapagliflozin or Empagliflozin 
Preferred: Dapagliflozin or Empaglif...
Dulaglutide or S/C Semaglutide
Dulaglutide or S/C Semaglutide
NWL
NWL
Metformin
Metformin
NWL
NWL
SGLT2 inhibitors
SGLT2 inhibitors
NWL
NWL
GLP-1 Receptor Agonists
GLP-1 Receptor Agonists
NWL
NWL
Basal insulin
Basal insulin
Starting and reviewing
Starting and reviewing
NWL
NWL
Sulfonylurea
Sulfonylurea
NWL
NWL
Summary of anti-diabetic agents
Summary of anti-diabetic agents
NWL
NWL
Dose adjustment in renal/hepatic impairment
Dose adjustment in renal/hepatic impairment
Insulin pen devices
Insulin pen devices
NWL
NWL
Insulin regimens
Insulin regimens
NWL
NWL
BD mixed insulin
BD mixed insulin
Starting and reviewing
Starting and reviewing
NWL
NWL
Indications for insulin
Indications for insul...
Insulin initiation
Insulin initiat...
Choice of insulin
Choice of insulin
NWL
NWL
Structured Education
Structured Education
Diet & Lifestyle first line therapy
Diet & Lifestyle first line the...
Remission
Remission
Weight loss and lifestyle change
Weight loss and lifestyle change
Sick day guidance
Sick day guidance
+ DPP4i
NWL
NWL
DPP4 inhibitors
DPP4 inhibitors
+/- Sulfonylurea
NWL
NWL
Sulfonylurea
Sulfonylurea
Text is not SVG - cannot display
+
+
+
+
+
+
+
Manage Symptomatic Hyperglycaemia
GLP-1 RA shortage guidance
If intolerant move down to next level
If intolerant move down to next l...
AND
AND
Metformin+ SGLT2i
STOP DPP4i
STOP DPP4i
NWL
NWL
New Diagnosis and Early insulin initiation
New Diagnosis and Early insulin initiat...
NWL
NWL
Screening and Diagnosis
Screening and Diagnosis
T1D vs T2D
T1D vs T2D
MODY
MODY
NWL
NWL
Algorithm
Algorithm
NWL
NWL
NWL
NWL
HbA1c targets
HbA1c targets
NWL
NWL
Hypoglycaemic agents with insulin
Hypoglycaemic agents with insulin
NWL
NWL
Sequential insulin strategies
Sequential insulin strategies
+ GLP-1 RA+ Sulfonylurea+ Basal Insulin
Preferred: Dapagliflozin
Preferred: Dapagliflozin
Dulaglutide or S/C Semaglutide
Dulaglutide or S/C Semaglutide
NWL
NWL
Metformin
Metformin
NWL
NWL
SGLT2 inhibitors
SGLT2 inhibitors
NWL
NWL
GLP-1 Receptor Agonists
GLP-1 Receptor Agonists
NWL
NWL
Basal insulin
Basal insulin
Starting and reviewing
Starting and reviewing
NWL
NWL
Sulfonylurea
Sulfonylurea
NWL
NWL
Summary of anti-diabetic agents
Summary of anti-diabetic agents
NWL
NWL
Dose adjustment in renal/hepatic impairment
Dose adjustment in renal/hepatic impairment
Insulin pen devices
Insulin pen devices
NWL
NWL
Insulin regimens
Insulin regimens
NWL
NWL
BD mixed insulin
BD mixed insulin
Starting and reviewing
Starting and reviewing
NWL
NWL
Indications for insulin
Indications for insul...
Insulin initiation
Insulin initiat...
Choice of insulin
Choice of insulin
NWL
NWL
Structured Education
Structured Education
Diet & Lifestyle first line therapy
Diet & Lifestyle first line the...
Remission
Remission
Weight loss and lifestyle change
Weight loss and lifestyle change
Sick day guidance
Sick day guidance
+ DPP4i
NWL
NWL
DPP4 inhibitors
DPP4 inhibitors
+/- Pioglitazone
NWL
NWL
Pioglitazone
Pioglitazone
Alternative: Canagliflozin
Alternative: Canagliflo...
*Guideline update due soon
*Guideline update due soon
Text is not SVG - cannot display
+
+
+
+
+
+
+
Manage Symptomatic Hyperglycaemia
GLP-1 RA shortage guidance
NICE GUIDELINES NG28
Metformin SGLT2iDPP4iPioglitazoneSulfonylureaInsulinGLP-1 RAInsulin
When dual therapy has not continued to control HbA1c to below the person's
individually agreed threshold, also consider insulin-based therapy (with or without other drugs).
When dual therapy has not continued to control HbA1c to below the per...
 Or if GI disturbance Metformin MR
Or if GI disturbance Metformin...
If Metformin not tolerated or contraindicated move down to the next step
If Metformin not tolerated or contraindicated mo...
NICE
NICE
Consider the criteria for switching one drug* for a GLP-1 mimetic
Consider the criteria for switching one drug* for a GLP-1 mimet...
*STOP DPP4i
*STOP DPP4i
HbA1c above individualised target
HbA1c above individualised target
DPP4iPioglitazoneSulfonylureaSGLT2i
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
NICE
NICE
Insulin-based treatments
Insulin-based treatments
Target = 53 mmol/mol
Target = 53 mmol/mol
NICE
NICE
Target = 48 mmol/mol
Target = 48 mmol/mol
NICE
NICE
NICE
NICE
Rescue therapy
Rescue therapy
Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a sulfonylurea and review when blood glucose control has been achieved.
Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a...
NICE
NICE
Diet and lifestyle advice
Diet and lifestyle advi...
At each point reinforce advice about diet and lifestyle.
At each point reinforce advice about diet and lifes...
Text is not SVG - cannot display
+
+
+
+
+
+
+
+
+
+
+
+
Manage Symptomatic Hyperglycaemia
GLP-1 RA shortage guidance
Metformin SGLT2iDPP4iPioglitazoneSulfonylureaInsulinGLP-1 RAInsulin
When dual therapy has not continued to control HbA1c to below the person's
individually agreed threshold, also consider insulin-based therapy (with or without other drugs).
When dual therapy has not continued to control HbA1c to below the per...
 Or if GI disturbance Metformin MR
Or if GI disturbance Metformin...
If Metformin not tolerated or contraindicated move down to the next step
If Metformin not tolerated or contraindicated mo...
NICE
NICE
1.7.10
1.7.10
NICE
NICE
Consider the criteria for switching one drug* for a GLP-1 mimetic
Consider the criteria for switching one drug* for a GLP-1 mimet...
*STOP DPP4i
*STOP DPP4i
HbA1c above individualised target
HbA1c above individualised target
NICE
NICE
1.7.17
1.7.17
DPP4iPioglitazoneSulfonylureaSGLT2i
NICE
NICE
1.7.19
1.7.19
NICE
NICE
1.7.21
1.7.21
Reviewing drug treatments
Reviewing drug treatments
Reviewing drug treatments
Reviewing drug treatments
Reviewing drug treatments
Reviewing drug treatments
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
NICE
NICE
Insulin-based treatments
Insulin-based treatments
NICE
NICE
First-line drug treatment
First-line drug treatment
NICE
NICE
Adopt an individualised approach
Adopt an individualised approa...
to diabetes care and
to diabetes care and
offer structured education
offer structured educati...
NICE
NICE
Measure HbA1c 3 - 6 monthly
Measure HbA1c 3 - 6 monthly
and
and
agree an individual HbA1c target
agree an individual HbA1c targ...
Target = 53 mmol/mol
Target = 53 mmol/mol
NICE
NICE
Target = 48 mmol/mol
Target = 48 mmol/mol
NICE
NICE
NICE
NICE
Rescue therapy
Rescue therapy
Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a sulfonylurea and review when blood glucose control has been achieved.
Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a...
NICE
NICE
Diet and lifestyle advice
Diet and lifestyle advi...
At each point reinforce advice about diet and lifestyle.
At each point reinforce advice about diet and lifes...
NICE
NICE
Choosing drug treatments
Choosing drug treatments
Text is not SVG - cannot display
+
+
+
+
+
+
+
+
+
+
+
+
Manage Symptomatic Hyperglycaemia
GLP-1 RA shortage guidance
If Metformin not tolerated or contraindicated move down to the next step
If Metformin not tolerated or contraindicated mo...
Target = 48 mmol/mol
Target = 48 mmol/mol
NICE
NICE
 Start metformin alone to assess tolerability before adding an SGLT2 inhibitor
Start metformin alone to assess tolerab...
Metformin ++ SGLT2iInsulinGLP-1 RAInsulin
When dual therapy has not continued to control HbA1c to below the person's
individually agreed threshold, also consider insulin-based therapy (with or without other drugs).
When dual therapy has not continued to control HbA1c to below the per...
 Or if GI disturbance Metformin MR
Or if GI disturbance Metformin...
NICE
NICE
1.7.10
1.7.10
NICE
NICE
Consider the criteria for switching one drug* for a GLP-1 mimetic
Consider the criteria for switching one drug* for a GLP-1 mimet...
*STOP DPP4i
*STOP DPP4i
HbA1c above individualised target
HbA1c above individualised target
NICE
NICE
1.7.17
1.7.17
NICE
NICE
1.7.19
1.7.19
NICE
NICE
1.7.21
1.7.21
Reviewing drug treatments
Reviewing drug treatments
Reviewing drug treatments
Reviewing drug treatments
Reviewing drug treatments
Reviewing drug treatments
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
NICE
NICE
Insulin-based treatments
Insulin-based treatments
NICE
NICE
First-line drug treatment
First-line drug treatment
NICE
NICE
Adopt an individualised approach
Adopt an individualised approa...
to diabetes care and
to diabetes care and
offer structured education
offer structured educati...
NICE
NICE
Measure HbA1c 3 - 6 monthly
Measure HbA1c 3 - 6 monthly
and
and
agree an individual HbA1c target
agree an individual HbA1c targ...
Target = 53 mmol/mol
Target = 53 mmol/mol
NICE
NICE
NICE
NICE
Rescue therapy
Rescue therapy
Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a sulfonylurea and review when blood glucose control has been achieved.
Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a...
NICE
NICE
Diet and lifestyle advice
Diet and lifestyle advi...
At each point reinforce advice about diet and lifestyle.
At each point reinforce advice about diet and lifes...
NICE
NICE
Choosing drug treatments
Choosing drug treatments
DPP4iPioglitazoneSulfonylurea
NICE
NICE
High risk of developing CVD
High risk of developing CVD
Consider adding SGLT2i as soon as metfomin tolerability is confirmed
Consider adding SGLT2i as soon as metfomin tolerability is conf...
NICE
NICE
SGLT2i with CV benefit
SGLT2i with CV benefit
1.7.5
1.7.5
Text is not SVG - cannot display
+
+
+
+
+
+
+
+
Manage Symptomatic Hyperglycaemia
GLP-1 RA shortage guidance
If Metformin not tolerated or contraindicated move down to the next step
If Metformin not tolerated or contraindicated mo...
Target = 48 mmol/mol
Target = 48 mmol/mol
NICE
NICE
 Start metformin alone to assess tolerability before adding an SGLT2 inhibitor
Start metformin alone to assess tolerab...
Metformin ++ SGLT2iInsulinGLP-1 RAInsulin
When dual therapy has not continued to control HbA1c to below the person's
individually agreed threshold, also consider insulin-based therapy (with or without other drugs).
When dual therapy has not continued to control HbA1c to below the per...
 Or if GI disturbance Metformin MR
Or if GI disturbance Metformin...
NICE
NICE
Consider the criteria for switching one drug* for a GLP-1 mimetic
Consider the criteria for switching one drug* for a GLP-1 mimet...
*STOP DPP4i
*STOP DPP4i
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
NICE
NICE
Insulin-based treatments
Insulin-based treatments
Target = 53 mmol/mol
Target = 53 mmol/mol
NICE
NICE
NICE
NICE
Rescue therapy
Rescue therapy
Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a sulfonylurea and review when blood glucose control has been achieved.
Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a...
NICE
NICE
Diet and lifestyle advice
Diet and lifestyle advi...
At each point reinforce advice about diet and lifestyle.
At each point reinforce advice about diet and lifes...
DPP4iPioglitazoneSulfonylurea
NICE
NICE
High risk of developing CVD
High risk of developing CVD
Consider adding SGLT2i as soon as metfomin tolerability is confirmed
Consider adding SGLT2i as soon as metfomin tolerability is conf...
NICE
NICE
SGLT2i with CV benefit
SGLT2i with CV benefit
1.7.5
1.7.5
Text is not SVG - cannot display
+
+
+
+
+
+
+
+
Manage Symptomatic Hyperglycaemia
GLP-1 RA shortage guidance
If Metformin not tolerated or contraindicated move down to the next step
If Metformin not tolerated or contraindicated mo...
Target = 48 mmol/mol
Target = 48 mmol/mol
NICE
NICE
 Start metformin alone to assess tolerability before adding an SGLT2 inhibitor
Start metformin alone to assess tolerab...
Metformin ++ SGLT2iInsulinGLP-1 RAInsulin
When dual therapy has not continued to control HbA1c to below the person's
individually agreed threshold, also consider insulin-based therapy (with or without other drugs).
When dual therapy has not continued to control HbA1c to below the per...
 Or if GI disturbance Metformin MR
Or if GI disturbance Metformin...
NICE
NICE
1.7.10
1.7.10
NICE
NICE
Consider the criteria for switching one drug* for a GLP-1 mimetic
Consider the criteria for switching one drug* for a GLP-1 mimet...
*STOP DPP4i
*STOP DPP4i
HbA1c above individualised target
HbA1c above individualised target
NICE
NICE
1.7.17
1.7.17
NICE
NICE
1.7.19
1.7.19
NICE
NICE
1.7.21
1.7.21
Reviewing drug treatments
Reviewing drug treatments
Reviewing drug treatments
Reviewing drug treatments
Reviewing drug treatments
Reviewing drug treatments
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
NICE
NICE
Insulin-based treatments
Insulin-based treatments
NICE
NICE
First-line drug treatment
First-line drug treatment
NICE
NICE
Adopt an individualised approach
Adopt an individualised approa...
to diabetes care and
to diabetes care and
offer structured education
offer structured educati...
NICE
NICE
Measure HbA1c 3 - 6 monthly
Measure HbA1c 3 - 6 monthly
and
and
agree an individual HbA1c target
agree an individual HbA1c targ...
Target = 53 mmol/mol
Target = 53 mmol/mol
NICE
NICE
NICE
NICE
Rescue therapy
Rescue therapy
Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a sulfonylurea and review when blood glucose control has been achieved.
Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a...
NICE
NICE
Diet and lifestyle advice
Diet and lifestyle advi...
At each point reinforce advice about diet and lifestyle.
At each point reinforce advice about diet and lifes...
NICE
NICE
Choosing drug treatments
Choosing drug treatments
DPP4iPioglitazoneSulfonylurea
NICE
NICE
Heart Failure or ASCVD
Heart Failure or ASCVD
OFFER SGLT2i as soon as metfomin tolerability is confirmed
OFFER SGLT2i as soon as metfomin tolerability is confir...
NICE
NICE
SGLT2i with CV benefit
SGLT2i with CV benefit
1.7.5
1.7.5
Text is not SVG - cannot display
+
+
+
+
+
+
+
+
Manage Symptomatic Hyperglycaemia
GLP-1 RA shortage guidance
If Metformin not tolerated or contraindicated move down to the next step
If Metformin not tolerated or contraindicated mo...
Target = 48 mmol/mol
Target = 48 mmol/mol
NICE
NICE
 Start metformin alone to assess tolerability before adding an SGLT2 inhibitor
Start metformin alone to assess tolerab...
Metformin ++ SGLT2iInsulinGLP-1 RAInsulin
When dual therapy has not continued to control HbA1c to below the person's
individually agreed threshold, also consider insulin-based therapy (with or without other drugs).
When dual therapy has not continued to control HbA1c to below the per...
 Or if GI disturbance Metformin MR
Or if GI disturbance Metformin...
NICE
NICE
Consider the criteria for switching one drug* for a GLP-1 mimetic
Consider the criteria for switching one drug* for a GLP-1 mimet...
*STOP DPP4i
*STOP DPP4i
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
HbA1c above individualised target
NICE
NICE
Insulin-based treatments
Insulin-based treatments
Target = 53 mmol/mol
Target = 53 mmol/mol
NICE
NICE
NICE
NICE
Rescue therapy
Rescue therapy
Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a sulfonylurea and review when blood glucose control has been achieved.
Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a...
NICE
NICE
Diet and lifestyle advice
Diet and lifestyle advi...
At each point reinforce advice about diet and lifestyle.
At each point reinforce advice about diet and lifes...
DPP4iPioglitazoneSulfonylurea
NICE
NICE
Heart Failure or ASCVD
Heart Failure or ASCVD
OFFER SGLT2i as soon as metfomin tolerability is confirmed
OFFER SGLT2i as soon as metfomin tolerability is confir...
NICE
NICE
SGLT2i with CV benefit
SGLT2i with CV benefit
1.7.5
1.7.5
Text is not SVG - cannot display
+
+
+
+
+
+
+
+
Manage Symptomatic Hyperglycaemia
GLP-1 RA shortage guidance
Consider initiating insulin in patients with:
  • Evidence of ongoing catabolism (e.g., unexpected weight loss)
  • Symptoms of hyperglycemia
  • Very high HbA1c (>86 mmol/mol) or blood glucose levels (≥16.7 mmol/L)
Consider initiating insulin in patients with:...
Consider immediate insulin start
Consider immediate insulin start
ADA
ADA
in most individuals
in most individuals
HbA1c above individual target
HbA1c above individual target
On dual/triple therapy
On dual/triple ther...
GLP-1 RA
GLP-1 RA
or dual GIP/GLP-1 RA agent
or dual GIP/GLP-1 RA agent
NICE
NICE
in certain circumstances
in certain circumstances
Insulin
Insulin
ADA
ADA
9.22
9.22
Basal Insulin
Basal Insulin
Basal Plus Insulin regimen
Basal Plus Insulin regimen
Premixed Insulin
Premixed Insulin
Titration
Titration
Intensification
Intensification
Titration
Titration
Titration
Titration
Intensification
Intensification
Intensification
Intensification
GLP-1 RA
GLP-1 RA
Basal Plus 2
Basal Plus 2
Premixed TDS
Premixed TDS
Basal Bolus Regimen
Basal Bolus Regimen
NICE
NICE
NICE
NICE
specialist care
specialist care
specialist care
specialist care
Insulin Types & Available Medicinal Forms in the UK
Insulin Types & Available Medicinal Forms in the...
May 2024
May 2024
UK GLP-1 RA shortage guidance 
UK GLP-1 RA shortage guidance 
HOW TO use GLP-1 RA therapy safely and effectively
HOW TO use GLP-1 RA therapy safely and effectively
PCDS
PCDS
CPD
CPD
The six steps to insulin safety
The six steps to insulin safety
PCDS
PCDS
At a glance factsheet: Tirzepatide for management of T2D
At a glance factsheet: Tirzepatide for management of T2D
PCDS
PCDS
At a glance factsheet: Impaired hypoglycaemia awareness
At a glance factsheet: Impaired hypoglycaemia awaren...
HOW TO assess fitness to drive
HOW TO assess fitness to drive
HOW TO minimise insulin errors
HOW TO minimise insulin errors
HOW TO support best practice injection technique
HOW TO support best practice injection technique
HOW TO calculate the amount of insulin to prescribe/month
HOW TO calculate the amount of insulin to prescribe/month
HOW TO prevent, identify and manage Hypoglycaemia
HOW TO prevent, identify and manage Hypoglycaemia
Text is not SVG - cannot display
Which insulin regimen should be chosen?
+
Consider immediate insulin start
BG
BG
BG
BG
18:00
18:00
12:00
12:00
09:00
09:00
06:00
06:00
03:00
03:00
00:00
00:00
21:00
21:00
15:00
15:00
18:00
18:00
21:00
21:00
00:00
00:00
03:00
03:00
06:00
06:00
09:00
09:00
Humulin M3
Humulin M3
~ 30 minutes before meal
~ 30 minutes before meal
1
1
2
2
3
3
4
4
5
5
6
6
7
7
8
8
9
9
10
10
11
11
12
12
Humulin M3
Humulin M3
~ 30 minutes before meal
~ 30 minutes before meal
1
1
2
2
3
3
4
4
5
5
6
6
7
7
8
8
9
9
10
10
11
11
12
12
Pre-bed
Pre-bed
Pre-breakfast
Pre-breakfast
CBG (mmol/L)
CBG (mmol...
Pre-lunch
Pre-lunch
Pre-Evening meal
Pre-Evening meal
Reduce evening meal insulin by 10%
Reduce evening meal insulin by 10%
< 4
< 4
Reduce breakfast insulin by 10%
Reduce breakfast insulin by 10%
*Reduce evening meal insulin by 10%
*Reduce evening meal i...
No change
No change
4 - 7
4 - 7
No change
No change
*Increase evening meal insulin by 10%
*Increase evening meal...
Increase evening meal insulin by 10%
Increase evening meal...
7.1 - 14
7.1 - 14
Increase breakfast insulin by 10%
Increase breakfast insulin by 10%
Increase evening meal insulin by 15%
Increase evening meal insulin by 15%
14.1 - 20
14.1 - 20
Increase breakfast insulin by 15%
Increase breakfast insulin by 15%
Increase evening meal insulin by 20%
Increase evening meal insulin by 20%
> 20
> 20
Increase breakfast insulin by 20%
Increase breakfast insulin by 20%
BG
BG
BG
BG
BG
BG
BG
BG
Text is not SVG - cannot display

Current insulin doses Humulin M3 10 units before breakfast + Humulin M3 10 units before evening meal

Hidden
Please enter a number from 0 to 200.
Hidden
Please enter a number from 0 to 200.
×

Header

London
Paris
Tokyo

London

London is the most populous city in the United Kingdom, with a metropolitan area of over 9 million inhabitants.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Paris

Paris is the capital of France.

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Tokyo

Tokyo is the capital of Japan.


Close
×

Header

Mirpur
Paris
Tokyo

Mirpur

Mirpur is a city in Pakistan.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Paris

Paris is the capital of France.

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Tokyo

Tokyo is the capital of Japan.


Close
×

Metformin

Close
×

Sulfonylurea

Close
×

SGLT2 inhibitor

Close
×

DPP4 inhibitor

Close
×

Pioglitazone

Close
×

GLP-1 RA

Close
×

Insulin for Type 2 Diabetes

Close
×

Dose adjustment in CKD and Liver imparement

Close
×

Which insulin regimen should be chosen?

UK: NICE and NWL
ADA 2024
Practical Guidance
NICE NG28 Insulin recommendations and NWL insulin recommendation
Basal insulin alone is the most convenient initial insulin treatment
ADA 2024 Insulin recommendations
ADA 2024 Pathway: Intensifying to injectable therapies in type 2 diabetes
Adapted from Wu T, et al. (2015), licensed under CC BY 4.0
Adapted from Wu T, et al. (2015), licensed under CC BY 4.0
Barriers to initiating insulin therapy
Barriers to initiating insulin therapy
Preparing Patients for Insulin Therapy
Preparing Patients for Insulin Therapy
  • Patients may fear initiating insulin for various reasons:
    • Fear of hypoglycaemia
    • Fear of weight gain
    • Concern that insulin therapy indicates severe complications (blindness, limb amputation, kidney failure)
    • Resistance to blood glucose monitoring
    • Belief that starting insulin indicates personal failure
  • Important to allay these fears.
  • Essential to select the right HbA1c target for individual patients.
  • If the HbA1c target is set too low, patients may omit insulin to avoid hypoglycemia, compromising their glycaemic control.
Patients may fear initiating insulin for various reasons:...
Wu T, et al. (2015)
Wu T, et al. (2015)
Patient factors to consider when deciding whether to use
premix insulin analog or basal insulin for initiation (based on consensus)
Patient factors to consider when deciding whether to use...
Patient factors to consider when deciding whether to use premix insulin analog or basal insulin for initiation (based on consensus). The figure shows both immediately applicable factors and other factors that will determine whether future intensification should be with basal–bolus or premix insulin analog therapy
Patient factors to consider when deciding whether to use premix insulin analog or basal insulin for initiation (based on...
Text is not SVG - cannot display
Close
https://local.clinicalpathways.io/clinical-craft-cards-insulin/